Skye Bioscience, Inc Common Stock

Yahoo Finance • 9 days ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today ann... Full story

Yahoo Finance • 23 days ago

PIMCO Intermediate Municipal Bond Exchange-Traded Fund (MUNI) Shares Cross Above 200 DMA

In trading on Friday, shares of the PIMCO Intermediate Municipal Bond Exchange-Traded Fund ETF (Symbol: MUNI) crossed above their 200 day moving average of $51.51, changing hands as high as $51.73 per share. PIMCO Intermediate Municipal B... Full story

Yahoo Finance • last month

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host... Full story

Yahoo Finance • last month

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

SAN DIEGO, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today anno... Full story

Yahoo Finance • last month

Skye initiated at overweight at Evercore on obesity asset nimacimab

[Wall street.] bodrumsurf * Evercore ISI is bullish on the prospects for Skye Bioscience (NASDAQ:SKYE [https://seekingalpha.com/symbol/SKYE]) due to its development of the CB1 inhibitor nimacimab for obesity. * The firm has a $10 pric... Full story

Yahoo Finance • 2 months ago

Skye Bioscience signals late Q3/early Q4 top-line Phase IIa results as nimacimab advances obesity treatment platform

Earnings Call Insights: Skye Bioscience (SKYE) Q2 2025 MANAGEMENT VIEW * Punit S. Dhillon, President and CEO, highlighted the imminent reporting of Phase IIa data for nimacimab, describing the quarter as a "notable prelude to our repor... Full story

Yahoo Finance • 2 months ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025Patient enrollment in Skye’s CBeyondTM Phase 2a obesity trial extension study initiated Independent Data Safety Monitoring Committee com... Full story

Yahoo Finance • 2 months ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

SAN DIEGO, July 30, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on advancing new therapeutic pathways for obesity and other metabolic health disorders, will host... Full story

Yahoo Finance • 3 months ago

Skye Bioscience stock jumps after JMP reiterates bullish stance

Investing.com - Skye Bioscience (NASDAQ:SKYE) shares surged approximately 30% Tuesday following increased attention on its weight loss drug nimacimab at the American Diabetes Association conference. JMP Securities reiterated its Market Ou... Full story

Yahoo Finance • 3 months ago

Skye confirms phase 2 data on nimacimab for obesity expected later this year

[Obesity card in hands of Medical Doctor] Michail_Petrov-96/iStock via Getty Images Phase 2a data on Skye Bioscience's (NASDAQ:SKYE [https://seekingalpha.com/symbol/SKYE]) cannabinoid-1 receptor blocker (CB1) for obesity, nimacimab, shoul... Full story

Yahoo Finance • 3 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

SAN DIEGO, June 17, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today anno... Full story

Yahoo Finance • 4 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today annou... Full story

Yahoo Finance • 4 months ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today annou... Full story

Yahoo Finance • 5 months ago

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host a... Full story

Yahoo Finance • 5 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced that on April 23,... Full story

Yahoo Finance • 6 months ago

Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removed... Full story

Yahoo Finance • 7 months ago

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

SAN DIEGO, March 14, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, will host... Full story

Yahoo Finance • 7 months ago

Skye Bioscience to Participate in SXSW Session on Obesity

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, is ple... Full story

Yahoo Finance • 7 months ago

Skye Bioscience to Present at TD Cowen Health Care Conference

SAN DIEGO, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders... Full story